Physician profile
Norman Lavin
NPI 1811902786
$68,556.12
in general payments reported to CMS, 2019-2025
30 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $8,084 · 2021: $17K · 2022: $20K · 2023: $965 · 2024: $957 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53,078.12 | 2019-2025 | Sogroya, Norditropin, Ozempic |
| Abbvie INC. | $11,455.19 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $1,040.21 | 2022-2025 | Skytrofa, Yorvipath |
| Tolmar Pharmaceuticals, INC. | $323.11 | 2021-2022 | |
| Pfizer INC. | $304.79 | 2019-2025 | |
| Tolmar, INC. | $273.30 | 2023-2025 | Fensolvi |
| Tandem Diabetes Care, INC. | $255.90 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $209.37 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $208.87 | 2020-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $194.53 | 2023-2025 | Omnipod |
| Medtronic, INC. | $159.38 | 2021-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $157.44 | 2023-2025 | |
| Mannkind Corporation | $132.42 | 2020-2022 | |
| Zealand Pharma US, INC. | $106.41 | 2021-2022 | |
| Lilly USA, LLC | $100.91 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $95.42 | 2020-2024 | Gvoke Hypopen |
| Soleno Therapeutics, INC. | $75.89 | 2025 | Vykat Xr |
| Ipsen Biopharmaceuticals, INC | $48.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.83 | 2019 | |
| Companion Medical, INC. | $42.52 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $41.16 | 2023-2025 | Baqsimi |
| Kyowa Kirin, INC. | $36.15 | 2025 | |
| Amarin Pharma, INC. | $35.00 | 2019 | |
| Arkray USA, INC. | $21.47 | 2023 | |
| Azurity Pharmaceuticals, INC. | $20.71 | 2024 | Triptodur |
| Sobi, INC | $20.20 | 2019 | |
| Lifescan, INC. | $19.33 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.32 | 2023 | |
| Medtronic Minimed, INC. | $18.05 | 2020 | |
| Amgen INC. | $17.79 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Lavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.